Home About Us Management Product Pipeline Collaborators Contact Us
Menutext


Pipeline


Candidate & Indication
Developmental Stage
Pre-clinical
Toxicology
Phase 1
Phase 2
PLAP; injection formulation enhance cancer treatments reduce muscle wasting and cachexia in cancer patients
Exit after Phase 1 or Phase 2
PLAP; oral formulation to treat metabolic syndrome and muscle wasting in obese/type 2 diabetic elderly patients
Exit after Phase 1
PLAP; skin formulation promote diabetic wound healing
Develop fully
PLAP; skin formulation treat inflammatory/infectious skin conditions (acne, shingles, herpes, psoriasis)
human proof of principle studies have already been done in all cases
Continue studies